Physician profile
Paul S Phillips
NPI 1073538153
$14,180.48
in general payments reported to CMS, 2019-2025
29 companies · $4,084 in 2025
The $4,084 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $300 · 2021: $778 · 2022: $873 · 2023: $937 · 2024: $6,456 · 2025: $4,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $2,432 · Honoraria: $45.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $2,431.99 |
| Honoraria | $45.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $10,496.69 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Alcon Vision LLC | $1,444.65 | 2019-2025 | Clareon, Wavelight Refractive Suite, Wavelight |
| New World Medical,INC. | $386.88 | 2021-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $375.07 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Dompe US, INC. | $374.91 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $138.15 | 2022-2024 | Infuse, Miebo, Vyzulta |
| Glaxosmithkline, LLC. | $125.00 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $112.56 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $73.75 | 2021-2023 | Acthar |
| Oyster Point Pharma, INC. | $61.84 | 2022-2024 | Tyrvaya |
| Astellas Pharma US INC | $59.81 | 2025 | Izervay |
| Ocular Therapeutix, INC. | $59.62 | 2022-2024 | Dextenza |
| Coopervision INC. | $52.47 | 2019 | |
| Biotissue Holdings INC. | $51.18 | 2021-2023 | |
| Alimera Sciences, INC. | $45.84 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.73 | 2019-2021 | |
| Horizon Therapeutics Plc | $40.42 | 2019-2020 | |
| Harrow Eye, LLC | $37.00 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $30.73 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $28.01 | 2019 | |
| Sandoz INC. | $19.32 | 2024 | Cimerli |
| Ani Pharmaceuticals, INC. | $18.42 | 2025 | Iluvien |
| Amgen INC. | $18.34 | 2025 | Tepezza |
| Lumibird Medical INC. | $16.66 | 2025 | |
| Abbvie INC. | $15.16 | 2023 | |
| Shire North American Group INC | $14.91 | 2019 | |
| Kala Pharmaceuticals, INC. | $14.53 | 2022 | |
| Glaukos Corporation | $14.01 | 2024 | Radius |
| Allergan, INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.